Twist Bioscience (TWST) IPO Opens 7% Lower

Today's IPO for Twist Bioscience Corporation (NASDAQ: TWST) opened for trading at $13 after pricing 5,000,000 shares of its common stock at a price to the public of $14.00 per share.

In addition, Twist has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price, less the underwriting discounts and commissions.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Allen & Company LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. The company is leveraging their unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sample (NGS) preparation, and antibody libraries for drug discovery and development. They are also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. We make products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

You May Also Be Interested In